Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells

Brain Research

Volumn 1196, Issue , 2008, Pages 22-32

  Li, Jing ^a   Vause, Carrie V ^a   Durham, Paul L ^a  

^a MISSOURI STATE UNIVERSITY   (United States)

Author keywords

CGRP; Glia; iNOS; NO; RAMP1; Trigeminal

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCITONIN GENE RELATED PEPTIDE[8-37]; CYCLIC AMP; FORSKOLIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; FEMALE; GLIA CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; TRIGEMINUS GANGLION;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORSKOLIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; NEUROGLIA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TRIGEMINAL GANGLION;

RATTUS;

EID: 39149112474     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.12.028     Document Type: Article

References (58)

1. Amara S., Jonas V., Rosenfeld M., Ong E., and Evans R. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298 (1982) 240-244
2. Amir R., and Devor M. Chemically mediated cross-excitation in rat dorsal root ganglia. J. Neurosci. 16 (1996) 4733-4741
3. Amir R., and Devor M. Functional cross-excitation between afferent A- and C-neurons in dorsal root ganglia. Neuroscience 95 (2000) 189-195
4. Bellamy J., Bowen E., Russo A., and Durham P. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur. J. Neurosci. 23 (2006) 2057-2066
5. Bellamy J., Cady R., and Durham P. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 46 (2006) 24-33
6. Bowen E., Schmidt T., Firm C., Russo A., and Durham P. Tumor necrosis factor-α stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem. 96 (2006) 65-77
7. Buzzi M. Trigeminal pain pathway: peripheral and central activation as experimental models of migraine. Funct. Neurol. 16 (2001) S77-S81
8. DeLeo J., and Yezierski R. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90 (2001) 1-6
9. Dodick D., and Silberstein S. Central sensitization theory of migraine: clinical implications. Headache 46 (2006) S182-S191
10. Dolly J., and Aoki K. The structure and mode of action of different botulinum toxins. Eur. J. Neurol. 13 Suppl 4 (2006) 1-9
11. Dowson A., Mathew N., and Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int. J. Clin. Pract. 60 (2006) 698-706
12. Dublin P., and Hanani M. Satellite glial cells in sensory ganglia: their possible contribution to inflammatory pain. Brain Behav. Immun. (2007)
13. Durham P., and Russo A. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J. Neurosci. 19 (1999) 3423-3429
14. Durham P., and Russo A. Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons. J. Neurosci. 23 (2003) 807-815
15. Durham P., Cady R., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44 (2004) 35-42
16. Edvinsson L., and Goadsby P. Neuropeptides in migraine and cluster headache. Cephalalgia 14 (1994) 320-327
17. Faraci F., and Heistad D. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol. Rev. 78 (1998) 53-97
18. Ferrari M.D. Migraine. Lancet 351 (1998) 1043-1051
19. Fiebich B., Lieb K., Engels S., and Heinrich M. Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. J. Neuroimmunol. 132 (2002) 18-24
20. Goadsby P., and Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine. Cephalalgia 11 (1991) 3-4
21. Goadsby P., and Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33 (1993) 48-56
22. Goadsby P., and Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 117 (1994) 427-434
23. Guo W., Wang H., Watanabe M., Shimizu K., Zou S., LaGraize S., Wei F., Dubner R., and Ren K. Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J. Neurosci. 27 (2007) 6006-6018
24. Hanani M. Satellite glial cells in sensory ganglia: from form to function. Brain Res. Brain Res. Rev. 48 (2005) 457-476
25. Kozuka N., Kudo Y., and Morita M. Multiple inhibitory pathways for lipopolysaccharide- and pro-inflammatory cytokine-induced nitric oxide production in cultured astrocytes. Neuroscience 144 (2007) 911-919
26. Lassen L., Haderslev P., Jacobsen V., Iversen H., Sperling B., and Olesen J. CGRP may play a causative role in migraine. Cephalalgia 22 (2002) 54-61
27. Lazarov N. Comparative analysis of the chemical neuroanatomy of the mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Prog. Neurobiol. 66 (2002) 19-59
28. Leabu M. Membrane fusion in cells: molecular machinery and mechanisms. J. Cell. Mol. Med. 10 (2006) 423-427
29. Lipton R., Stewart W., Diamond S., Diamond M., and Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41 (2001) 646-657
30. Liu B., Gao H., Wang J., Jeohn G., Cooper C., and Hong J. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. N. Y. Acad. Sci. 962 (2002) 318-331
31. Mallee J., Salvatore C., LeBourdelles B., Oliver K., Longmore J., Koblan K., and Kane S. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J. Biol. Chem. 277 (2002) 14294-14298
32. Markovic M., Miljkovic D., and Trajkovic V. Regulation of inducible nitric oxide synthase by cAMP-elevating phospho-diesterase inhibitors. Curr. Drug Targets Inflamm. Allergy 2 (2003) 63-79
33. Matsuka Y., Neubert J., Maidment N., and Spigelman I. Concurrent release of ATP and substance P within guinea pig trigeminal ganglia in vivo. Brain Research 915 (2001) 248-255
34. Meller S., Dykstra C., Grzybycki D., Murphy S., and Gebhart G. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 33 (1994) 1471-1478
35. Murphy S. Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia 29 (2000) 1-13
36. Neubert J.K., Maidment N.T., Matsuka Y., Adelson D.W., Kruger L., and Spigelman I. Inflammation-induced changes in primary afferent-evoked release of substance P within trigeminal ganglia in vivo. Brain Res. 871 (2000) 181-191
37. Olesen J., Diener H., Husstedt I., Goadsby P., Hall D., Meier U., Pollentier S., and Lesko L. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350 (2004) 1104-1110
38. Paakkari I., and Lindsberg P. Nitric oxide in the central nervous system. Ann. Med. 27 (1995) 369-377
39. Pannese E. Perikaryal surface specializations of neurons in sensory ganglia. Int. Rev. Cytol. 220 (2002) 1-34
40. Pietrobon D. Migraine: new molecular mechanisms. Neuroscientist 11 (2005) 373-386
41. Platten M., Wick W., Wischhusen J., and Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). Br. J. Pharmacol. 134 (2001) 1279-1284
42. Poyner D., Sexton P., Marshall I., Smith D., Quirion R., Born W., Muff R., Fischer J., and Foord S. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 54 (2002) 233-246
43. Rosenfeld M., Mermod J.J., Amara S., Swanson L., Sawchenko P., Rivier J., Vale W., and Evans R. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304 (1983) 129-135
44. Saha R., and Pahan K. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxidants & Redox Signaling 8 (2006) 929-947
45. Shankland W. The trigeminal nerve. Part I: an over-view. Cranio 18 (2000) 238-248
46. Snyder D., Kelly M., and Woodbury D. SNARE complex regulation by phosphorylation. Cell Biochem. Biophys. 45 (2006) 111-123
47. Takeda M., Tanimoto T., Kadoi J., Nasu M., Takahashi M., Kitagawa J., and Matsumoto S. Enhanced excitability of nociceptive trigeminal ganglion neurons by satellite glial cytokine following peripheral inflammation. Pain 129 (2007) 155-166
48. Thalakoti S., Patil V., Damodaram S., Vause C., Langford L., Freeman S., and Durham P. Neuron-Glia signaling in trigeminal ganglion: Implications for migraine pathology. Headache 47 (2007) 1008-1023
49. van Rossum D., Hanisch U., and Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci. Biobehav. Rev. 21 (1997) 649-678
50. Watkins L., and Maier S. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol. Rev. 82 (2002) 981-1011
51. Watkins L., Milligan E., and Maier S. Spinal cord glia: new players in pain. Pain 93 (2001) 201-205
52. Watkins L., Milligan E., and Maier S. Glial activation: a driving force for pathological pain. Trends Neurosci. 24 (2001) 450-455
53. Wieseler-Frank J., Maier S., and Watkins L. Glial activation and pathological pain. Neurochem. Int. 45 (2004) 389-395
54. Wimalawansa S. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocrine Reviews 17 (1996) 533-585
55. Won J., Im Y., Singh A., and Singh I. Dual role of cAMP in iNOS expression in glial cells and macrophages is mediated by differential regulation of p38-MAPK/ATF-2 activation and iNOS stability. Free Radic. Biol. Med. 37 (2004) 1834-1844
56. Yun H.Y., Dawson V., and Dawson T. Neurobiology of nitric oxide. Crit. Rev. Neurobiol. 10 (1996) 291-316
57. Zhang Z., Winborn C., Marquez de Prado B., and Russo A. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J. Neurosci. 27 (2007) 2693-2703
58. Zidek Z. Role of cytokines in the modulation of nitric oxide production by cyclic AMP. Eur. Cytokine Netw. 12 (2001) 22-32